Jim Fenton

Investor Relations Contact at Association for Accessible Medicines

Consumer Services

Commercial Services

Profile

Jim Fenton is currently the Senior Vice President-Government Affairs at the Association for Accessible Medicines.
He completed his undergraduate degree at the University of Oregon and another undergraduate degree at Georgetown University.

Jim Fenton active positions

Companies	Position	Start
Association for Accessible Medicines Association for Accessible Medicines Miscellaneous Commercial ServicesCommercial Services The Association for Accessible Medicines is an organization that aims to make generic and biosimilar medicines more accessible to those who need them. The organization is based in Arlington, VA. The non-profit company believes that increasing competition is the key to tackling the high cost of prescription drugs, rather than shifting costs among healthcare stakeholders. In 2022, generic and biosimilar prescription medicines saved $408 billion for the healthcare system overall, with more than $2.90 trillion saved over the past 10 years. The company was founded by Milan Puskar, Robert R. Grusky. David Gaugh has been the CEO of the company since 2012.	Investor Relations Contact	-

All active positions of Jim Fenton

Training of Jim Fenton

Georgetown University	Undergraduate Degree
University of Oregon	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jim Fenton's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Association for Accessible Medicines Association for Accessible Medicines Miscellaneous Commercial ServicesCommercial Services The Association for Accessible Medicines is an organization that aims to make generic and biosimilar medicines more accessible to those who need them. The organization is based in Arlington, VA. The non-profit company believes that increasing competition is the key to tackling the high cost of prescription drugs, rather than shifting costs among healthcare stakeholders. In 2022, generic and biosimilar prescription medicines saved $408 billion for the healthcare system overall, with more than $2.90 trillion saved over the past 10 years. The company was founded by Milan Puskar, Robert R. Grusky. David Gaugh has been the CEO of the company since 2012.	Commercial Services